An SNRI, or serotonin-norepinephrine reuptake inhibitor, is a type of antidepressant that works by increasing levels of two chemical messengers in the brain: serotonin and norepinephrine. These medications are among the most commonly prescribed treatments for depression, but they’re also used for anxiety disorders, chronic pain conditions, and other issues. Understanding how they work, what they treat, and what to expect can help you make sense of a prescription or a conversation with your provider.
How SNRIs Work in the Brain
Your brain cells communicate by releasing chemical messengers called neurotransmitters into the tiny gaps between them. After a message is sent, the sending cell normally reabsorbs (or “reuptakes”) those chemicals, recycling them. SNRIs block this recycling process for two specific neurotransmitters: serotonin, which helps regulate mood and emotional stability, and norepinephrine, which plays a role in alertness, energy, and the body’s pain signaling pathways.
By preventing reabsorption, SNRIs keep more serotonin and norepinephrine available in those gaps, strengthening the signals between brain cells. This dual action is what distinguishes SNRIs from SSRIs (selective serotonin reuptake inhibitors), which only target serotonin. The added effect on norepinephrine is one reason SNRIs are sometimes chosen for people dealing with fatigue, concentration problems, or chronic pain alongside depression.
Not all SNRIs affect the two neurotransmitters equally. Venlafaxine has roughly a 30-fold stronger effect on serotonin than norepinephrine, meaning it acts more like an SSRI at lower doses and only engages norepinephrine significantly at higher doses. Duloxetine has about a 10-fold preference for serotonin. Among SNRIs, milnacipran (used in some countries but not FDA-approved for depression in the U.S.) has a balanced 1:1 ratio, affecting both chemicals more equally.
FDA-Approved SNRIs
Four SNRIs are currently approved in the United States for treating depression:
- Venlafaxine (Effexor XR): also approved for generalized anxiety disorder, social anxiety disorder, and panic disorder
- Duloxetine (Cymbalta): also approved for generalized anxiety disorder and certain pain conditions, including fibromyalgia
- Desvenlafaxine (Pristiq): a metabolite of venlafaxine, approved for major depressive disorder
- Levomilnacipran (Fetzima): approved for major depressive disorder
What SNRIs Treat Beyond Depression
The dual action on serotonin and norepinephrine gives SNRIs a broader range of uses than many other antidepressants. Both neurotransmitters are involved in the body’s pain processing pathways, which is why these medications are effective for certain chronic pain conditions. Duloxetine was the first antidepressant to receive FDA approval for fibromyalgia, and it’s also approved for diabetic nerve pain. Venlafaxine has shown effectiveness in clinical trials for neuropathic pain and tension-type headaches.
SNRIs are also used off-label for menopausal hot flashes. The North American Menopause Society has recommended both desvenlafaxine and venlafaxine as appropriate options for women who can’t take or prefer to avoid hormone therapy. These medications can reduce the frequency and severity of hot flashes, though they aren’t specifically FDA-approved for that purpose (a low-dose SSRI called paroxetine holds that distinction).
How SNRIs Differ From SSRIs
SSRIs and SNRIs are both considered first-line treatments for depression, and they share a similar safety profile compared to older antidepressants. The key difference is scope: SSRIs affect only serotonin, while SNRIs add norepinephrine to the equation. In practice, this means SNRIs may be a better fit for people whose depression involves prominent physical symptoms like fatigue, body aches, or difficulty concentrating, since norepinephrine is closely tied to energy and alertness.
The side effect profiles also differ slightly. Both classes commonly cause gastrointestinal issues and sexual dysfunction. SNRIs, however, carry an additional risk of raising blood pressure, particularly at higher doses. This is a direct consequence of increased norepinephrine activity, since norepinephrine also affects blood vessel tone. If you’re taking an SNRI, periodic blood pressure checks are a reasonable precaution.
Common Side Effects
Nausea is the most frequently reported side effect of SNRIs, occurring in roughly 26% of people in clinical studies. It tends to be worst during the first week or two and often improves as your body adjusts. Other common side effects include sweating, dry mouth, dizziness, constipation, and fatigue. Sexual side effects, including reduced desire and difficulty reaching orgasm, affect a meaningful percentage of users and are less likely to resolve on their own over time.
Because norepinephrine plays a role in the body’s “fight or flight” system, some people experience increased heart rate, elevated blood pressure, or heightened anxiety when starting an SNRI. These effects tend to be dose-dependent, meaning they’re more pronounced at higher doses. Starting at a low dose and increasing gradually helps minimize early side effects.
How Long SNRIs Take to Work
Most people won’t feel a meaningful difference in the first few days. Some initial improvement in sleep, appetite, or energy can appear within the first one to two weeks, but the full effect on mood typically takes four to eight weeks. Research shows that an early response, defined as at least a 20% drop in depression severity within the first two to four weeks, is a good predictor of reaching full remission by 8 to 12 weeks.
If you’ve been on an SNRI for four weeks without any noticeable change, that’s worth discussing with your prescriber. Switching medications before four weeks is generally not recommended because the response can be delayed, but a complete absence of improvement by that point may signal the need for a dose adjustment or a different medication.
Stopping an SNRI Safely
SNRIs should not be stopped abruptly. Doing so can cause discontinuation syndrome, a cluster of uncomfortable symptoms that typically appears within a few days of stopping or significantly reducing the dose. The symptoms are sometimes summarized with the mnemonic FINISH: flu-like symptoms (fatigue, headaches, sweating), insomnia with vivid dreams, nausea, imbalance (dizziness or vertigo), sensory disturbances (tingling, “electric shock” sensations sometimes called “brain zaps”), and hyperarousal (anxiety, irritability, agitation).
Tapering over six to eight weeks significantly reduces the risk. Short-acting SNRIs like venlafaxine are more likely to cause discontinuation symptoms than longer-acting options, and they typically require a more gradual taper. If you’ve only been on an SNRI for a few weeks or are on a very low dose, a faster taper may be possible. If symptoms become severe during tapering, the standard approach is to go back to the previous dose and slow down the process.
Discontinuation syndrome is not the same as addiction. It reflects your nervous system readjusting to the absence of a medication it has adapted to, not a craving or dependency in the way that term is commonly understood.